Corresponding Author: Eric X. Chen, MD, PhD, Princess Margaret Cancer Center, 700 University Ave, Rm 7-824, Toronto, ON M5G 1X6 Canada (firstname.lastname@example.org).
Accepted for Publication: March 2, 2020.
Published Online: May 7, 2020. doi:10.1001/jamaoncol.2020.0910
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2020 Chen EX et al. JAMA Oncology.
Author Contributions: Drs Chen and O’Callaghan had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Chen, Jonker, Loree, Ahmad, Kavan, Tu, O'Callaghan.
Acquisition, analysis, or interpretation of data: Chen, Jonker, Loree, Kennecke, Berry, Couture, Goffin, Kavan, Harb, Colwell, Samimi, Samson, Abbas, Aucoin, Aubin, Koski, Wei, Magoski, Tu, O'Callaghan.
Drafting of the manuscript: Chen, Jonker, Loree, Ahmad, Kavan, Abbas.
Critical revision of the manuscript for important intellectual content: Chen, Jonker, Loree, Kennecke, Berry, Couture, Goffin, Kavan, Harb, Colwell, Samimi, Samson, Aucoin, Aubin, Koski, Wei, Magoski, Tu, O'Callaghan.
Statistical analysis: Loree, Tu, O'Callaghan.
Obtained funding: Jonker, Aucoin, O'Callaghan.
Administrative, technical, or material support: Chen, Jonker, Loree, Kennecke, Couture, Goffin, Samimi, Aucoin, Aubin, Wei, Magoski, O'Callaghan.
Supervision: Jonker, Ahmad, Kavan, Samimi, Abbas, Aubin, Koski, O'Callaghan.
Conflict of Interest Disclosures: Dr Chen participated in clinical trials sponsored by Merck, BMS, Boston Biomedical, AZ, and received research support (drugs only) from AZ. Dr Chen received honoraria from Eisai and Taiho. Dr Loree received research support from Ipsen and honoraria from Ipsen, Amgen, Bayer, Novartis, and Taiho. Dr Samson received honorarium from Taiho. Dr Goffin received honoraria from Merck and Amgen and nonfinancial support from AZ. Dr Samimi received honoraria from Amgen, Celgene, Ipsen, Apobiologix, Eisai, Taiho, and Roche. Dr Aubin received honoraria from Taiho, Shire, Amgen, BMS, and Celgene, and participated in clinical trials sponsored by Merck and BMS. Dr Aucoin received honoraria from AZ, Roche, BMS, Amgen, Takeda, Pfizer, Taiho, Celgene. Dr Wei received honoraria from Shire and Celgene, and nonfinancial support from Bayer. All other authors declared no competing interests.
Data Sharing Statement: See Supplement 3.
Funding/Support: AstraZeneca provided durvalumab and tremelimumab and contributed partial funding for this study. The Canadian Cancer Trials Group (CCTG) is funded by the Canadian Cancer Society.
Role of the Funder/Sponsor: AstraZeneca was consulted on design of the study, and reviewed a draft of the manuscript. It played no role in conduct of the study; collection, management, analysis, and interpretation of the data; preparation, or approval of the manuscript; and decision to submit the manuscript for publication.
Meeting Presentation: Presented at ASCO GI Symposium, January 19, 2019, San Francisco, California; and at ASCO Annual Meeting, June 3, 2019, Chicago, Illinois.
F , Ferlay
J , Soerjomataram
I , Siegel
RL , Torre
LA , Jemal
A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin
. 2018;68(6):394-424. doi:10.3322/caac.21492
AP , Niedzwiecki
D , Lenz
et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. JAMA
. 2017;317(23):2392-2401. doi:10.1001/jama.2017.7105
S , Modest
DP , Rossius
et al; FIRE-3 investigators. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. Lancet Oncol
. 2016;17(10):1426-1434. doi:10.1016/S1470-2045(16)30269-8
A , Van Cutsem
E , Sobrero
et al; CORRECT Study Group. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet
. 2013;381(9863):303-312. doi:10.1016/S0140-6736(12)61900-X
MJ , McDermott
R , Leach
et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol
. 2017;18(9):1182-1191. doi:10.1016/S1470-2045(17)30422-9
MJ , Lonardi
S , Wong
et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol
. 2018;36(8):773-779. doi:10.1200/JCO.2017.76.9901
E , Artieri
C , Vowles
et al. Analytical validation of a comprehensive 500-gene ctDNA panel designed for immuno-oncology and DNA damage research. Cancer Res
. 2018;78(13)(suppl−Abstr 5603):5603.Google Scholar
K , Helman
E , Nance
T , Artieri
C , Yen
J , Zhao
et al. Development and analytical validation of a plasma-based tumor mutational burden (TMB) score from next-generation sequencing panels. Ann Oncol
. 2018;29(suppl 8):131P. doi:10.1093/annonc/mdy269.129Google ScholarCrossref
A , Barbacioru
C , Chudova
D , Helman
E , Sikora
M , Artieri
et al. Microsatellite instability detection by targeted sequencing of cell-free DNA. Ann Oncol
. 2018;29(suppl 8):1190. doi:10.1093/annonc/mdy288.063Google ScholarCrossref
P , Bottomley
A ; EORTC Quality of Life Group; Quality of Life Unit; European Organisation for Research and Treatment of Cancer. Quality of life research within the EORTC-the EORTC QLQ-C30. Eur J Cancer
. 2002;38(suppl 4):S125-S133. doi:10.1016/S0959-8049(01)00448-8
JM , Jonker
DJ , Feilotter
H , Kennecke
HF , Brohawn
PZ , Banks
et al. Impact of clonality and DNA repair mutations on plasma tumour mutation burden (pTMB) and immunotherapy efficacy in microsatellite stable (MSS) metastatic colorectal cancer (mCRC) in CCTG CO.26. Ann Oncol
. 2019;30(Suppl 5):200. doi:10.1093/annonc/mdz246.006Google ScholarCrossref
F , Ou
FS , Qu
et al. Mutational analysis of patients with colorectal cancer in CALGB/SWOG 80405 identifies new roles of microsatellite instability and tumor mutational burden for patient outcome. J Clin Oncol
. 2019;37(14):1217-1227. doi:10.1200/JCO.18.01798
T , Durán
I , van der Heijden
et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet
. 2018;391(10122):748-757. doi:10.1016/S0140-6736(17)33297-X
AB , Ouyang
C , Sandhu
et al. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. Ann Oncol
. 2019;30(7):1096-1103. doi:10.1093/annonc/mdz134
S , Cho
BC , Reinmuth
et al. Tumor mutational burden (TMB) as a biomarker of survival in metastatic non-small cell lung cancer (mNSCLC): Blood and tissue TMB analysis from MYSTIC, a Phase III study of first-line durvalumab ± tremelimumab vs chemotherapy. In: Proceedings of the 110th Annual Meeting of the American Association for Cancer Research, 2019; Altanta. Abstract: CT074.
S , Hara
H , Takahashi
et al. Regorafenib plus nivolumab in patients with advanced gastric (GC) or colorectal cancer (CRC): an open label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603). J Clin Oncol
. 2019;37(15):2522. doi:10.1200/JCO.2019.37.15_suppl.2522
NB , Twohy
E , Ou
FS , Halfdanarson
TR , Lenz
HJ , Breakstone
et al. BACCI: a phase II randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) in refractory metastatic colorectal cancer (mCRC): an ACCRU network study. Ann Oncol
. 2019;30(Suppl 5):533. doi:10.1093/annonc/mdz246.011Google ScholarCrossref